Predict your next investment

Private Equity
tullisfunds.com

See what CB Insights has to offer

Investments

96

Portfolio Exits

25

Funds

9

About Tullis Health Investors

Tullis Health Investors is a private equity firm that specializes in the healthcare industry. Within health care, Tullis focuses onbiotechnology and life sciences, pharmaceuticals, health care services, andmedical devices. Tullis Health Investors operates two funds - The Tullis Opportunity Funds which invests in late-stage health care deals where liquidity may be foreseen within approximately a two to four-year horizon. They also operate Tullis-Dickerson Capital Focus funds which invest in healthcare companies at all stages of growth.

Tullis Health Investors Headquarter Location

55 Old Field Point Road

Greenwich, Connecticut, 06830,

United States

203-629-8799

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Tullis Health Investors News

Surefire Medical Raises $15M Series C

Dec 3, 2015

Surefire Medical Raises $15M Series C 12/2/15 Surefire Medical , Inc., a commercial stage company developing a new class of direct-to-tumor delivery systems employed in minimally invasive interventional procedures, announced today the closing of $15M Series C financing. The round, led by Tullis Health Investors , will be used for a global launch of the new Surefire Precision, a device specifically designed to meet the clinical need for targeted delivery systems in the treatment of primary liver cancer (HCC). "Tullis Health Investors looks forward to working with Surefire Medical on domestic and international commercial expansion, in particular the opportunity for Surefire in China," said John Tullis, Partner at Tullis Health Investors. "With more than 50 percent of global primary liver cancer cases occurring in China, the launch of the Precision is positioning Surefire to drive adoption by physicians performing embolization procedures, and may also help to decrease overall treatment costs. " KMG Capital Partners, Partisan Management Group, MCG Partners, High Country Ventures and angel investors also participated in the financing. Approximately 80 percent of the more than 700,000 liver cancers diagnosed annually worldwide are inoperable, requiring alternative treatment. Surefire Medical's technology is currently being used in more than 100 hospitals in the U.S. and in 14 countries worldwide by interventional radiologists performing minimally invasive chemoembolization and radioembolization procedures in treating both primary and secondary (metastatic) liver cancer. Incidence of liver cancer, the third most common cause of cancer deaths, continues to rise due to metastasis and rising hepatitis B and C incidence. "With the closing of this Series C Financing and our collaboration with the Tullis team, we are launching our innovative and new Precision technology to physicians worldwide for treatment of primary liver cancers," said James Chomas, President and CEO of Surefire Medical. "The growing body of clinical evidence suggests that increasing the amount of therapeutic agents delivered into the tumor may improve patient response and overall survival. With the Surefire technology, more of the dose reaches the tumor while sparing healthy tissue. " Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the Interventional Radiology and the Interventional Oncology markets. Surefire's technology is designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip, which collapses during forward flow to allow normal blood flow to carry therapy as close to the tumor as possible. In reverse flow, when drugs/microspheres are being delivered by the system, the tip automatically and dynamically expands to the vessel wall, creating a pressure gradient that drives the therapeutic agents deeply into the tumor while blocking backflow that might damage healthy tissue. The Surefire Infusion Systems and Surefire Precision have received regulatory approval in the U.S., Europe, Canada, Australia, New Zealand,Taiwan, Mexico and Brazil. www.surefiremedical.com Stories you Need to Know Stories you Need to Know It's on us. Share your news here.

Tullis Health Investors Investments

96 Investments

Tullis Health Investors has made 96 investments. Their latest investment was in Circular Genomics as part of their Seed VC on December 12, 2021.

CBI Logo

Tullis Health Investors Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/9/2021

Seed VC

Circular Genomics

$1.55M

Yes

3

2/1/2019

Series G

Exagen

$6.59M

No

1

1/25/2018

Private Equity

SafeOp Surgical

$5.65M

No

1

10/7/2015

Series B

Subscribe to see more

$99M

Subscribe to see more

10

6/23/2015

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/9/2021

2/1/2019

1/25/2018

10/7/2015

6/23/2015

Round

Seed VC

Series G

Private Equity

Series B

Series C

Company

Circular Genomics

Exagen

SafeOp Surgical

Subscribe to see more

Subscribe to see more

Amount

$1.55M

$6.59M

$5.65M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

1

1

10

10

Tullis Health Investors Portfolio Exits

25 Portfolio Exits

Tullis Health Investors has 25 portfolio exits. Their latest portfolio exit was OrthoSensor on January 05, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/5/2021

Acquired

$99M

11

9/19/2019

IPO

$99M

Public

1

1/16/2019

Asset Sale

$99M

1

10/9/2018

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

3/9/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/5/2021

9/19/2019

1/16/2019

10/9/2018

3/9/2018

Exit

Acquired

IPO

Asset Sale

Acq - Fin

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

11

1

1

10

10

Tullis Health Investors Fund History

9 Fund Histories

Tullis Health Investors has 9 funds, including Tullis Growth Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/29/2015

Tullis Growth Fund

Late-Stage Venture Capital

Closed

$21.4M

2

8/25/2010

Tullis Opportunity Fund II LP

Subscribe to see more

Subscribe to see more

$99M

10

6/10/2009

Tullis Opportunity Fund LP

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2007

Tullis-Dickerson Capital Focus IV LP

Subscribe to see more

Subscribe to see more

10

9/1/2002

Tullis-Dickerson Capital Focus III LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

1/29/2015

8/25/2010

6/10/2009

12/31/2007

9/1/2002

Fund

Tullis Growth Fund

Tullis Opportunity Fund II LP

Tullis Opportunity Fund LP

Tullis-Dickerson Capital Focus IV LP

Tullis-Dickerson Capital Focus III LP

Fund Type

Late-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$21.4M

$99M

$99M

$99M

Sources

2

10

10

10

10

Tullis Health Investors Team

6 Team Members

Tullis Health Investors has 6 team members, including current Founder, Chief Executive Officer, James Tullis.

Name

Work History

Title

Status

James Tullis

Founder, Chief Executive Officer

Current

John L. Tullis

Chief Executive Officer

Current

Sandford D Smith

Managing Director

Current

Anthony Hunter

Chief Financial Officer

Former

Nora Mende

Chief Financial Officer

Former

Name

James Tullis

John L. Tullis

Sandford D Smith

Anthony Hunter

Nora Mende

Work History

Title

Founder, Chief Executive Officer

Chief Executive Officer

Managing Director

Chief Financial Officer

Chief Financial Officer

Status

Current

Current

Current

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.